Lv7
4744 积分 2022-11-08 加入
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
8小时前
已完结
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
16小时前
已完结
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
13天前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
14天前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
14天前
已完结
STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer
17天前
已完结
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
25天前
已完结
Revisiting Prophylactic Corticosteroids to Mitigate Severe Immune-Related Adverse Events in Hepatocellular Carcinoma
28天前
已完结
Revisiting Prophylactic Corticosteroids to Mitigate Severe Immune-Related Adverse Events in Hepatocellular Carcinoma
28天前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
29天前
已完结
皖公网安备34019202002308
